TEVA PHARMACEUTICALS

Teva Pharmaceuticals, a pharmaceutical company based both in Israel and the United States, specializing in the provision of generic drugs along with active pharmaceutical ingredients and propriety pharmaceuticals to a lesser extent.

Teva Pharmaceuticals has a rich history that dates back to 1935 when it was founded by Günther Friedländer, a German pharmacist, botanist and pharmacognosy, and his aunt, Else Kober.

The original registration of the company was made under the name Teva Middle East Pharmaceutical & Chemical Works Co., Ltd.

Built on 4,900 pounds sterling, which came from the family’s own capital along with loans from other German immigrants, Teva Pharmaceuticals became a public company in 1951 when Alfred Feuchtwanger joined the company as partner, making up for capital shortage.

During World War II, Teva Pharmaceuticals provided medicine to allied forces, particularly to the British Army which has a presence in the Middle East.

Teva Pharmaceuticals’ development was sparked when the High Commissioner for Palestine and Transjordan, Sir Alan Gordon Cunningham, promoted the company’s reputation in the pharmaceuticals market.

This came after having visited Teva Pharmaceuticals on behalf of the Secretary of State for the Colonies shortly after the war.

Teva Pharmaceuticals medicinal products were transported to Arabian countries during World War II until the British Mandatory Palestine regime was terminated and shortly after, in 1941, Teva Pharmaceuticals products were presented in Cairo, Egypt.

After the exhibition, Teva Pharmaceuticals’ products were exported to the United States Soviet Unition, Denmark, Persia, and Burma.

There was a partnership between Sintex, a Mexican company, Schering Plough, and Teva Pharmaceuticals in 1964 and during the same year a merger between Assia and Zori which resulted in a controlling stake in Teva Pharmaceuticals by 1968.

These three companies combined to form the modern-day Teva Pharmaceutical Industries, Ltd. and from 1980, Teva Pharmaceuticals started with what would be the first of many acquisitions when Ikapharm was purchased.

Between 1980 and 2000, Teva Pharmaceuticals acquired Plantex, Biogal Gyógyszenrgyár and Novopharm with 2003 bringing along the announcement with intentions to acquire Sicor, Inc. in a transaction amounting to $3.4 billion.

This acquisition was subsequently completed in early 2004 and marks Teva Pharmaceuticals’ point of entry into the biosimilars market.

During 2005, in Har Hotzvim, a technology park in Jerusalem, Teva Pharmaceuticals opened a new manufacturing plant along with seeing its entry into eh Japanese market in 2005, followed by the establishment of a joint venture in 2008 with Kowa.

The completion of the acquisition pertaining to IVAX Corporation for $7.4 billion saw completion in 2006 and by 2008, Teva Pharmaceuticals’ sales amounted to $11.08 billion with a subsequent increase in 2009 to $13.09 billion and $16.1 billion in 2010.

The plan to acquire Ratiopharm, was announced in March 2010, with the acquisition seeing completion in August of the same year.

Cephalon was purchased by Teva Pharmaceuticals in mid-2011 followed by several further acquisitions in years to come which included that of Taiyo Pharmaceutical Industry, MicroDose, Nupathe, Labrys Biologics and more.

Teva Pharmaceuticals oversees a high-value, extensive and vast product portfolio of pharmaceutical products which includes a variety of medicines manufactured and distributed worldwide.

Today, Teva Pharmaceuticals is not only the largest manufacturer of generic medicine, but it is also one of the largest pharmaceutical companies worldwide. The staff compliment reported for the 2018 period showed a total of 42,535 employees.

Teva Pharmaceuticals holds the position as the largest manufacturer of generic drugs worldwide in addition to holding patents on multiple drugs such as Copaxone which is used for the specific treatment of multiple sclerosis.

Despite having generic competition with Copaxone and seeing a decrease of 5% in revenues for 2019, revenues in turn increased again by 5% during the first quarter of 2025, which is undeniably quite the feat when faced with numerous competitors.

In addition to this, the FDA approved the Teva Pharmaceuticals’ autoinjector device which is used for Ajovy injection.

Teva Pharmaceuticals, through the years of its history since its inception, has seen substantial growth and development with expansion in its product base along with business through various and numerous acquisitions.

Sales of the drug Austedo, which is used in the treatment of tardive dyskinesia along with Huntington’s disease chorea have seen an increase of up to 64% YOY to approximately $122 million.

In addition, operating income was boosted 22% YOY with adjusted earnings per share up by 27% to $0.76 when Teva Pharmaceuticals cut expenses pertaining to sales and marketing, in addition to spending less on research and development.

Due to the emergence and spread of Covid-19 on a global scale and the nature of Teva Pharmaceutical’s business, the company has managed to draw positive investor attention resulting from hyped treatment for those who are critically ill with the virus.

Despite various drugs having at first believed to fight against the virus, and failed, investors have instead looked towards Teva Pharmaceuticals’ core strengths.

Teva Pharmaceuticals is actively providing support for Covid-19 treatment needs by actively assessing the portfolio along with directing the global manufacturing network towards the securing and scaled production of API and finished doses as potential treatments.

Despite the focus shift, Teva Pharmaceuticals is still strongly maintaining its vast portfolio of medicines to other patients right around the world while supporting any emerging needs that relate to the crisis in collaboration with governments and organizations.

The nature of Teva Pharmaceuticals’ business has put it at the frontline of aiding governments and organizations with conceited efforts while maintaining the reliable supply of high quality generic medicines to meet the rising critical demand.

Teva Pharmaceuticals trades its shares on the New York Stock Exchange (NYSE) under the stock symbol TEVA as well as on the Tel Aviv Stock Exchange (TASE) under the stock symbol TEVA.

Data pertaining to the analysis done on the market performance for the first quarter of 2025, which ended in March indicated revenues of $4.4 billion with a free cash flow of $551 million.

The GAAP diluted EPS recorded was $0.06 with a non-GAAP diluted EPS of $0.76 and despite uncertainty surrounding the Covid-19 pandemic, the full year 2025 business outlook has been reaffirmed.

Teva Pharmaceuticals’ business outlook indicates revenues of between $16.6 to $17 billion in addition to an EBITDA of between $4.5 to $4.9 billion and an EPS of between $2.30 to $2.55.

With sound financials and significant, consistent, and continuous growth forecasted for the remainder of 2025 quarters, shareholders who buy or sell shares can expect lucrative dividends and returns.

The efforts of governments in attempting to curb the virus is fully supported as Teva Pharmaceuticals has risen to the challenge while safeguarding the health and well-being of its own employees.

Healthcare

Pharmaceutical

Drug Manufacturers – Specialty and Generic

1. Navigate to the AvaTrade website and select ‘Register’
2. Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
3. As soon as your account application has been reviewed and approved, you can select your trading platform from AvaTrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
4. Once you have downloaded the trading platform of your choice, you can use your AvaTrade live account details to log into your AvaTrade account on the trading platform.
5. From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘Teva’ to buy/purchase shares.
6. Alternatively, you can make use of AvaTrade’s online Web Trader or the AvaTradeGo mobile application ( Available on Android and iOS)

Buying shares has never been this convenient and easy. #myfirstshare

View more global shares for sale – here.

• Leverage of up to 1:20
• Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
• Indices, stocks, and commodities can all be traded form a single screen.
• Client support is presented live in a multitude of languages.
• Traders have exclusive access to a variety of educational tools
• Trades can be executed across multiple platforms

More shares that can be purchased / traded through AvaTrade, can be viewed here.

• Can I buy Teva Pharmaceuticals shares in South Africa?
  Yes, you can.

• How to buy Teva Pharmaceuticals shares
  By simply opening a free account on SA Shares, or by clicking the “Buy this Share” button to get started.

• What is the current share price?
  By clicking on the link provided above, you can view the real-time Teva Pharmaceuticals share price on the platform.

• Is Teva Pharmaceuticals a good share to buy?
  Yes, it is. Due to the nature of its business, there is consistent and substantial growth forecasted for Teva Pharmaceuticals for the remainder of 2025 despite growing concerns of uncertainty that surround the spread and impact of Covid-19.

• Can I buy Teva Pharmaceuticals CFD through SA Shares?
  Yes, you can.